Testing effectiveness (Phase 2)Study completedNCT00003914What this trial is testingDolastatin 10 in Treating Patients With Advanced Kidney CancerWho this might be right forKidney Cancer Mayo Clinic 30
Early research (Phase 1)Active Not RecruitingNCT05704985What this trial is testingEvaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ TumorsWho this might be right forCancerSolid TumorColorectal Cancer+6 more DEKA Biosciences 39
Not applicableStudy completedNCT00927043What this trial is testingStudy Evaluating Renal Cell Carcinoma Risk FactorsWho this might be right forCarcinoma, Renal Cell Pfizer 145
Testing effectiveness (Phase 2)UnknownNCT03736330What this trial is testingAnti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal CarcinomaWho this might be right forRenal Cancer Metastatic Sun Yat-sen University 24
Early research (Phase 1)Study completedNCT03502330What this trial is testingAPX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaWho this might be right forAdvanced MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma Yale University 42
Testing effectiveness (Phase 2)Study completedNCT00678119What this trial is testingStudy Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma TreatmentWho this might be right forRenal Cell Carcinoma Argos Therapeutics 25
Not applicableLooking for participantsNCT07327489What this trial is testingPredicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)Who this might be right forCancerImmunotherapyAdvanced Solid Tumors Cancer+12 more Elephas 2,000
Testing effectiveness (Phase 2)Study completedNCT03200717What this trial is testingStudy of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor TreatmentWho this might be right forAdvanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma Novartis Pharmaceuticals 62
Early research (Phase 1)Not Yet RecruitingNCT07252661What this trial is testingStudy of ACC-1898 in Adult Participants With Advanced Solid TumorsWho this might be right forHepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, Medullary+6 more AccSalus Biosciences, Inc. 40
Early research (Phase 1)Study completedNCT01772004What this trial is testingAvelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)Who this might be right forSolid Tumors EMD Serono Research & Development Institute, Inc. 1,756
Early research (Phase 1)Study completedNCT01588678What this trial is testingA Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or LymphomasWho this might be right forAdvanced Solid TumorLymphoma Daiichi Sankyo 32
Not applicableActive Not RecruitingNCT03647878What this trial is testingStudy of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.Who this might be right forAdvanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma Ipsen 224
Testing effectiveness (Phase 2)Study completedNCT01282463What this trial is testingStudy of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaWho this might be right forCarcinoma of Urinary TractUrethral CarcinomaCarcinoma of Ureter+1 more Eli Lilly and Company 148
Not applicableStudy completedNCT04353765What this trial is testingStudy Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsWho this might be right forLocally Advanced or Metastatic Renal Cell Carcinoma Ipsen 247
Early research (Phase 1)Active Not RecruitingNCT04606472What this trial is testingSI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid TumorsWho this might be right forSolid Tumor Sichuan Baili Pharmaceutical Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05155033What this trial is testingPhase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaWho this might be right forMetastatic MelanomaAdvanced Locoregional MelanomaMetastatic Renal Cell Carcinoma+1 more National Cancer Institute (NCI) 78
Early research (Phase 1)Study completedNCT00066404What this trial is testingIntrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural EffusionsWho this might be right forCancer Abramson Cancer Center at Penn Medicine
Testing effectiveness (Phase 2)Ended earlyNCT01727336What this trial is testingStudy of Dalantercept and Axitinib in Patients With Advanced Renal Cell CarcinomaWho this might be right forAdvanced Renal Cell Carcinoma Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 160
Testing effectiveness (Phase 2)Looking for participantsNCT06682793What this trial is testingEvaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionWho this might be right forSolid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more A2 Biotherapeutics Inc. 240
Not applicableStudy completedNCT00836745What this trial is testingNon-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With SutentWho this might be right forRenal Cell Carcinoma Pfizer 36